Matrices Patents (Class 424/484)
  • Patent number: 10335487
    Abstract: This invention presents methods for targeting and killing types of cells or organisms using Magneto-Electric Nano-Particles under the control of an external magnetic field. A method was also presented for using Magneto-Electric Nano-Particles to stimulate or rejuvenate cells under an external magnetic field.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: July 2, 2019
    Inventor: Ping Liang
  • Patent number: 10322185
    Abstract: The present invention can provide a controlled drug release carrier formed by using a silk fibroin porous material, which has high drug controlled release rate, controllability of the drug controlled release speed, high strength, easy handleability, skin care properties from high biocompatibility, high water retentivity, and capability of efficiently retaining a drug.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: June 18, 2019
    Assignees: HITACHI CHEMICAL COMPANY, LTD., ST. MARIANNA UNIVERSITY, SCHOOL OF MEDICINE, NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES
    Inventors: Kazutoshi Kobayashi, Kunihiro Suto, Naosuke Sumi, Hajime Inoue, Yasushi Tamada
  • Patent number: 10322142
    Abstract: The present invention relates to stable polymer matrix compositions comprising high concentrations (from about 1.5% w/w to about 3.5% w/w) sodium hyaluronate obtained from a Streptococcus zooepidemicus source and a non-ionic polymer. The polymer matrix composition further comprises polyethylene glycol and methylparaben, and utilizes ingredients that are of pharmaceutical or compendial grade. The polymer matrix compositions may optionally comprise an active ingredient. The present polymer matrix compositions may be used in the treatment of wounds, burns, certain dermatological conditions, vaginal dryness, and in topical, transdermal delivery and sustained release of active ingredients.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: June 18, 2019
    Assignee: GLYCOBIOSCIENCES INC.
    Inventors: Kevin Drizen, Jai Velusamy
  • Patent number: 10314940
    Abstract: A collagen-based therapeutic delivery device includes an insoluble synthetic collagen-fibril matrix comprising a polymerization product of soluble oligomeric collagen or a polymerization product of a mixture of soluble oligomeric collagen with one or more type of non-oligomeric soluble collagen molecules, such as, for example, soluble telocollagen and/or soluble atelocollagen, and an active agent dispersed throughout the collagen-fibril matrix or within a portion of the collagen-fibril matrix. A pre-matrix composition includes an aqueous solution including soluble collagen-fibril building blocks and an active agent in the aqueous solution. The soluble collagen-fibril building blocks include soluble oligomeric collagen or a mixture of soluble oligomeric collagen with non-oligomeric soluble collagen molecules. The building blocks are operable to self-assemble into a macromolecular synthetic collagen-fibril matrix in the absence of an exogenous cross-linking agent.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: June 11, 2019
    Assignee: Purdue Research Foundation
    Inventor: Sherry Voytik-Harbin
  • Patent number: 10307430
    Abstract: The present invention relates to pharmaceutical compositions comprising an ATP-sensitive potassium (K ATP) channel antagonist (e.g., sulfonylureas, meglitinides) and methods for treating hyperglycaemia and/or promoting growth of a premature and/or small for gestational age infant.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: June 4, 2019
    Assignee: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Michel Polak, Marianne Berdugo Polak
  • Patent number: 10292997
    Abstract: The present invention relates to compositions and methods to improve the microenvironments in and around the wound in an effort to enhance healing. Specifically, the present invention comprises application of tissue and cells culture nutrient media, such as minimum essential media, supplemented with insulin and/or with substances exhibiting insulin-like activity, such as cinnamon or cinnamon extracts including but not limited to MHCP. The media is applied to the wound to stimulate the viable cells in the wound bed and the adjacent cells in the periphery of the wound to proliferate and grow into the wound in order to achieve wound closure.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: May 21, 2019
    Inventor: Ella Lindenbaum
  • Patent number: 10285936
    Abstract: The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: May 14, 2019
    Assignee: Laboratorios Farmacéuticos Rovi, S.A.
    Inventors: Guillermo Franco Rodríguez, Ibon Gutierro Aduriz
  • Patent number: 10279076
    Abstract: The present invention relates to a parenteral composition for maintaining the efficacy of a filler for a long time, containing a collagen hydrolysate as an active ingredient. The composition, according to the present invention, can maintain the efficacy of a hyaluronic acid filler for a longer time, thereby enabling the effect thereof to be maintained irrespective of a smaller frequency of filler operations, and thus there is an advantage of also reducing skin irritation. In addition, there is an advantage of enabling an immediate effect since an administration method is simple as a parenteral administration and enables direct penetration into the skin.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: May 7, 2019
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Hyun Jung Shin, Jin Kyu Choi, Byung Gyu Kim, Dae Bang Seo
  • Patent number: 10272057
    Abstract: The invention relates to layered double hydroxide (LDH) materials and in particular to new methods of preparing improved LDH materials which have intercalated active anionic compounds (improved LDH-active anion materials). The improved LDH-active anion materials are characterized by their high degree of robustness, demonstrated by their high Particle Robustness Factor values, and by their ability to retain substantially all of the intercalated active anionic compound, in the absence of ion exchange conditions and/or at pH>4.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: April 30, 2019
    Assignee: OXFORD PHARMASCIENCE LIMITED
    Inventors: Claire Thompson, Marcelo Leonardo Bravo Cordero, Dermot Michael O'Hare
  • Patent number: 10258566
    Abstract: The present invention relates to compositions, methods and kits for the treatment of bone particularly impaired or damaged bone.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: April 16, 2019
    Assignee: BIOMIMETIC THERAPEUTICS, LLC
    Inventors: Charles E. Hart, Jeffrey O. Hollinger, Samuel E. Lynch
  • Patent number: 10253203
    Abstract: Articles are provided comprising a substrate and a coating. The coating comprises a polyelectrolyte complex having surface roughness. The polyelectrolyte complex has a thickness of at least 10 micrometers and a roughness of at least 1 micrometer.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: April 9, 2019
    Assignee: The Florida State University Research Foundation, Inc.
    Inventor: Joseph B. Schlenoff
  • Patent number: 10244787
    Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a polymer matrix and one or more flavorants and/or active ingredients embedded in the polymer matrix. The polymer matrix can include a copolymer of ethylene and one or more vinyl monomers or zein. For example, the polymer can be ethylene-vinyl acetate copolymer and/or ethylene-vinyl alcohol copolymer. In some cases, the oral product can include tobacco and/or nicotine.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 2, 2019
    Assignee: Altria Client Services LLC
    Inventors: Munmaya K. Mishra, Georgios D. Karles
  • Patent number: 10226532
    Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: March 12, 2019
    Assignee: DURECT CORPORATION
    Inventors: Jeremy C. Wright, Wilma Tamraz, John J. Leonard, John W. Gibson, Keith E. Branham, Stefania Sjobeck, Brooks Boyd, Christopher M. Rubino
  • Patent number: 10213526
    Abstract: Provided are methods for preparing sterilized, gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth substrates. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: February 26, 2019
    Assignee: University of Pittsburgh-Of the Commonwealth System of Higher Education
    Inventors: Stephen F. Badylak, Christopher Lee Dearth, Timothy Joseph Keane, Jr., Neill Jordon Turner
  • Patent number: 10166254
    Abstract: The present invention relates to methods for treating and preventing graft-versus-host disease (GVHD) and radiation-induced tissue damage or organ failure. More particularly, methods of the present invention comprise administering a therapeutically effective amount of mesenchymal stem cell-educated macrophages (MEMs) to a subject to treat or prevent GVHD, bone marrow failure, radiation-induced tissue damage or organ failure, or a condition associated with aberrant inflammation.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: January 1, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Peiman Hematti, Myriam N. Bouchlaka, Christian M. Capitini
  • Patent number: 10154865
    Abstract: An orthopedic implant, such as a bone screw with a self-tapping thread, is formed of a biodegradable material such as a magnesium alloy. A bioactive surface coating is provided on the implant, such as at the threading. The coating contains micro-abrasives which assist with screw/implant penetration, and/or contains microcapsules containing lubricant, wherein the microcapsules rupture from pressure and frictional heat as the implant penetrates bone.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: December 18, 2018
    Assignee: BIOTRONIK AG
    Inventors: Ullrich Bayer, Daniel Lootz
  • Patent number: 10123530
    Abstract: The invention relates to the treatment of blood, blood products and organs for the removal and/or detoxification of amyloid-beta oligomers.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: November 13, 2018
    Assignee: FORSCHUNGSZENTRUM JUELICH GMBH
    Inventor: Dieter Willbold
  • Patent number: 10111810
    Abstract: The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: October 30, 2018
    Assignee: Aquestive Therapeutics, Inc.
    Inventors: Robert K. Yang, Richard C. Fuisz, Garry L. Myers, Joseph M. Fuisz
  • Patent number: 10045947
    Abstract: The invention provides polymer compositions for cell and drug delivery.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: August 14, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: Sidi A. Bencherif, David J. Mooney, David Edwards, Roger Warren Sands
  • Patent number: 10047154
    Abstract: An Ang2 specific antibody, a method of inhibiting angiogenesis or a method of treating a disease related to the activation and/or overproduction of Ang2 using the antibody, and a composition for diagnosing a disease related to the activation and/or overproduction of Ang2 including the antibody.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: August 14, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seok Kyun Kim, Sang Yeul Han, Kwang Hoon Lee, Kyung Eun Kim, Chung Ho Kim, Yong In Kim, Hyung-Chan Kim, Yoon Sook Lee, Hyo Seon Lee
  • Patent number: 10016428
    Abstract: The present invention refers to a pharmaceutical composition of sildenafil citrate in the form of a suspension for administration orally that comprises water as a vehicle and xanthan gum and hypromellose as suspension agents, that is highly stable and allows the efficient masking of the active ingredient's bitter taste. It also refers to a procedure for the preparation of said suspension and to a container that contains it and that is provided with a dosing device for its administration. This composition of sildenafil citrate in the form of a suspension is suitable for administration orally for the treatment of masculine sexual dysfunction.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: July 10, 2018
    Inventors: Fernando Martínez-Alzamora, Antonia Gómez Calvo, Miguel Rizo Martínez, Nuria Sanz Menéndez
  • Patent number: 10006003
    Abstract: The present technology provides methods for preparing a flowable amniotic composition derived from amniotic membrane of humans. Various embodiments of the method for preparing the amniotic composition may comprise mincing the amniotic membrane in a cryopreservation solution, cryopreservation, homogenization, filtration, centrifugation, and resuspension of a pellet in a cell solution to produce the flowable amniotic composition. The amniotic composition may comprise approximately 2.7 million viable cells per milliliter. The viability of the cells may be substantially stable for at least six months at ?18° C. Some preparations of the amniotic composition may have a flowability that may be at least partially characterized by a viscosity suitable for delivery to the target site through at least a 22 gauge needle.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 26, 2018
    Assignee: Surgenex, LLC
    Inventors: Eliott Spencer, Doug Schmid, Abel Bullock
  • Patent number: 10000742
    Abstract: The present disclosure generally relates to a method and device for inactivation and dry storage, under ambient conditions, of a biological sample containing RNA virus. Methods for collecting and recovering RNA from a biological sample and subsequent analysis for a virus are also provided.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: June 19, 2018
    Assignee: General Electric Company
    Inventors: Erik Leeming Kvam, Robert Scott Duthie, John Richard Nelson
  • Patent number: 9999705
    Abstract: The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, coated medical devices (e.g. stents, valves . . . ), vessels, tubular grafts, vascular grafts, wound healing devices including protein suture biomaterials and biomeshes, dental plugs and implants, skin/bone/tissue grafts, tissue fillers, protein biomaterial adhesion prevention barriers, cell scaffolding and other biocompatible biocoacervate or biomaterial devices.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: June 19, 2018
    Assignee: Gel-Del Technologies, Inc.
    Inventors: David B. Masters, Eric P. Berg
  • Patent number: 9987213
    Abstract: The present invention relates to the composition and method of use for the topical application of the potent androgen hormone dihydrotestosterone (DHT), used alone or in fixed combination with other hair growth medications; including other androgens, bimatoprost, other prostamides, prostaglandins, minoxidil or apocrine hair growth factors to promote and enhance hair growth of terminal mustache hair, beard hair, also chest hair, and other male androgen sensitive or dependent hair growth in humans or animals.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: June 5, 2018
    Inventor: Edward Dunne Corboy, Jr.
  • Patent number: 9968621
    Abstract: Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: May 15, 2018
    Assignee: Dr. Reddy's Laboratories Ltd.
    Inventors: Franklin Okumu, Jan-Jon Chu, Julie Ann Webb, Rafael Anthony Sabino, Andrew Xian Chen
  • Patent number: 9968552
    Abstract: Oral pharmaceutical dosage form comprising tromethamine and a NSAID selected from the group comprising ibuprofen, naproxen and flurbiprofen, characterized in that it also comprises a compound selected from the group comprising glycine, vitamin B6 and mixtures thereof.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: May 15, 2018
    Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F.S.p.A.
    Inventors: Leonardo Marchitto, Francesca Mariotti, Lorella Ragni
  • Patent number: 9943566
    Abstract: A novel NF-?B-inhibitor peptide is a component in a skin care composition comprising the NF-?B-inhibitor and a dermatologically acceptable carrier. The composition may also include at least one additional skin care active. Additionally, the composition may include a peptide that acts as a TGF-?1 mimic. Means for treating mature, languished skin with compositions comprising the peptide are also provided.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: April 17, 2018
    Assignee: Geoffrey Brooks Consultants, LLC
    Inventors: Geoffrey J. Brooks, Rajendra S. Bhatnagar, Andrew P. Banham
  • Patent number: 9937033
    Abstract: A method of corneal lenslet implantation with a cross-linked cornea is disclosed herein.
    Type: Grant
    Filed: August 7, 2016
    Date of Patent: April 10, 2018
    Inventor: Gholam A. Peyman
  • Patent number: 9933237
    Abstract: A pressure impulse mitigating barrier including a crosslinked gel, the gel including water and gelatin which has been crosslinked using a functional silane compound, the compound including an electrophilic group (where the electrophilic group is not a silane) and a group of formula (B) where R is a C1-10 alkyl group, C6-10 aryl group, or C7-12 arylalkyl group; R? is a C1-10 alkyl group, C6-10 aryl group, or C7-12 arylalkyl group; n is 0-1, and where the functional silane has Mw of 800 g/mol or less.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: April 3, 2018
    Assignee: BIODYNAMIC ARMOR LTD
    Inventor: Leonid Tarasoff
  • Patent number: 9926373
    Abstract: Provided are compositions and methods relating to human CD30L antigen binding proteins. Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions are also provided.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: March 27, 2018
    Assignees: Novo Nordisk A/S, Amgen Inc.
    Inventors: Mette D. Andersen, Jeff Dantzler, Richard J. Armitage, Rutilio Clark
  • Patent number: 9913927
    Abstract: Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: March 13, 2018
    Assignee: University of Utah Research Foundation
    Inventor: Russell J. Stewart
  • Patent number: 9902767
    Abstract: A method for the prevention and/or treatment of a disease accompanied by vascular leakage and/or vascular inflammation comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and forms a complex with a Tie2 receptor and Ang2.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: February 27, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hyo Seon Lee, Kyung Eun Kim, Seung Ja Oh, Sang Yeul Han
  • Patent number: 9884079
    Abstract: A Lactobacillus mali strain that can be used for treating a metabolic syndrome is provided. A method for treating obesity, diabetes or a complication of diabetes by using the Lactobacillus mali strain is also provided.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: February 6, 2018
    Assignee: National Taiwan University
    Inventors: Ming-Ju Chen, Yu-Chun Lin, Hsin-Hui Hsieh
  • Patent number: 9850461
    Abstract: The present invention relates to a hydrogel precursor formulation, its process of production as well as a kit comprising said formulation and a method of production of a hydrogel using said formulation. The precursor formulation comprises at least one structural compound, preferably vinyl sulfone (acrylated branched) poly(ethylene glycol), and at least one linker compound, preferably a peptide with two cysteines, wherein said structural compound and said linker compound are polymerizable by a selective reaction between a nucleophile and a conjugated unsaturated bond or group. The precursor formulation is in the form of a powder.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: December 26, 2017
    Assignee: QGEL SA
    Inventors: Simone Rizzi, Matthias Lutolf
  • Patent number: 9849219
    Abstract: Autografts are produced using material harvested from the patient without creation of a new wound. For example, material is harvested from the patient's very wound to which the autograft is to be applied.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: December 26, 2017
    Assignee: DERMAGENESIS, LLC
    Inventor: Sandra Berriman
  • Patent number: 9828422
    Abstract: An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: November 28, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Kyung Eun Kim, Seung Ja Oh, Hyo Seon Lee, Sang Yeul Han
  • Patent number: 9827272
    Abstract: Provided herein are hydrogel cell matrices, hydrogel cell matrix systems for the support, growth, and differentiation of a stem cell or progenitor cell and methods for making such hydrogel cell matrices.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: November 28, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Amit Kumar Jha, Kevin E. Healy
  • Patent number: 9801910
    Abstract: The present invention pertains to the development of biologically derived extracellular matrices (ECM) derived from decellularized pleura tissue. Such matrices are useful in many clinical and therapeutic applications, including the repair, reconstruction, sealing, or joining of tissue, tendons, bones, and/or ligaments. In addition, the present invention features methods of making a biologically derived ECM derived from decellularized pleura tissue. The invention further features laminated ECM matrices.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: October 31, 2017
    Assignee: Ethicon, Inc.
    Inventors: Sridevi Dhanaraj, Chandra M. Valmikinathan, Charito Buensuceso, Agnieszka Seyda
  • Patent number: 9795639
    Abstract: Methods for treating erectile dysfunction by administering a human birth tissue material composition are provided. The method includes the step of administering a human birth tissue material composition onto or into an affected penis.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: October 24, 2017
    Assignee: BioDLogics, LLC
    Inventor: Timothy R. Brahm
  • Patent number: 9763879
    Abstract: A control release and abuse-resistant opiate drug delivery oral wafer or edible oral film dosage to treat pain and substance abuse is provided. The drug delivery oral wafer or edible oral film dosage includes a controlled release layer containing enteric-release beads dispersed in a polymer matrix. The enteric-release beads are formed from a therapeutic amount of an opioid agonist and/or pharmaceutically acceptable salt thereof and a sub-therapeutic amount of opioid antagonist and/or pharmaceutically acceptable salt thereof coated or encapsulated in an enteric-release polymer. The controlled release polymer matrix dissolves or disintegrates following administration or consumption of the oral wafer or edible oral film, releasing the enteric-release beads to be swallowed, with subsequent absorption of the active ingredients within the patient's intestines.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: September 19, 2017
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventor: Michael Li
  • Patent number: 9757456
    Abstract: A pharmaceutical or cosmetic composition, comprising a substantially poorly water-soluble pharmaceutical active ingredient; and a nanoporous folic acid material, wherein the active pharmaceutical ingredient is incorporated inside the nanoporous channels of the particles.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: September 12, 2017
    Assignee: Nanologica AB
    Inventors: Chunfang Zhou, Xin Xia, Alfonso E. Garcia-Bennett
  • Patent number: 9744135
    Abstract: Compositions useful for making dosage forms capable of dissolving or disintegrating in less than 10 seconds without the need for conventional disintegrants and methods making and using the same are disclosed.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: August 29, 2017
    Assignee: Deseret Laboratories, Inc.
    Inventors: Robert F. Dickman, Scott Gubler, Tim Olds, R. Vance Wood, Usha Tuscano, Angel Gonzalez
  • Patent number: 9744189
    Abstract: Lithium is regarded as the gold standard comparator and benchmark treatment for mania. One of the problems associated with Lithium is its narrow therapeutic window. Recent attempts to find new drugs with similar therapeutic activities have yielded new chemical entities. However, these potential new drugs have yet to match the many bioactivities attributable to lithium's efficacy for the treatment of neuropsychiatric diseases. Consequently, an intense effort for re-engineering lithium therapeutics using cocrystallization is currently underway. The evaluation of pharmacokinetics of previously unexplored lithium salts with organic anions (lithium salicylate and lithium lactate) has found that these lithium salts exhibit profoundly different pharmacokinetics compared to the more common FDA approved salt, lithium carbonate, in rats.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: August 29, 2017
    Assignee: University of South Florida
    Inventors: Adam J. Smith, R. Douglas Shytle
  • Patent number: 9744163
    Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 29, 2017
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger, Joseph Niemann
  • Patent number: 9737569
    Abstract: ECM based compositions including amniotic membrane and methods for employing same to treat cardiovascular disorders.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: August 22, 2017
    Assignee: CorMatrix Cardiovascular, Inc.
    Inventor: Robert G Matheny
  • Patent number: 9737605
    Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 22, 2017
    Assignee: DURECT CORPORATION
    Inventors: Jeremy C. Wright, Wilma Tamraz, John J. Leonard, John W. Gibson, Keith E. Branham, Stefania Sjobeck, Brooks Boyd, Christopher M. Rubino
  • Patent number: 9724423
    Abstract: The present invention relates to shear-thinning ?-lactalbumin hydrogels, which have a threshold and are thixotropic, to a method for preparing same and to the use thereof.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: August 8, 2017
    Assignees: Commissariat a l'Energie Atomique et aux Energies Alternatives, Centre National de la Recherche Scientifique
    Inventors: Vincent Forge, Carole Mathevon, Frédéric Pignon
  • Patent number: 9724304
    Abstract: Provided is a nanosphere for delivery of a therapeutic agent comprising: a polymer matrix; discrete liquid oil droplets dispersed in the polymer matrix; and a therapeutic agent dissolved or dispersed in the oil. In some embodiments, the nanosphere is pegylated. In some embodiments, the nanosphere has a diameter of from about 100 nm to about 300 nm. In further preferred embodiments, the nanosphere has a diameter of from about 150 nm to about 250 nm. In yet further embodiments, the nanosphere has a diameter of from about 180 nm to about 220 nm. In some embodiments, the oil comprises a lipid or a phospholipid. In further embodiments, the lipid or the phospholipid has a melting point below 20° C. In some embodiments, the polymer is a natural, modified or synthetic polymer. In further embodiments, the polymer is biodegradable.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: August 8, 2017
    Assignee: TEMPLE UNIVERSITY—Of The Commonwealth System of Higher Education
    Inventors: Ho Lun Wong, Mayuri Narvekar, Hui Yi Xue
  • Patent number: 9706963
    Abstract: A heterogeneous multiple core control system for predictive medical monitoring is provided. The system includes a first processor platform that is optimized for serialized computation and a second processor platform that is optimized for parallelized computation. A memory stores instructions that are executed by either the first processor platform or the second processor platform to provide the functionality of the system. By executing the instructions, the system determines whether a condition of a first patient is to be monitored using a primarily parallelized model or a primarily serialized model. The predicted condition is calculated using the primarily parallelized model by executing the primarily parallelized model on the second processor platform. The predicted condition is calculated using the primarily serialized model by executing the primarily serialized model on the first processor platform.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: July 18, 2017
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Sandeep Gupta, Ayan Banerjee